United States Neuroendocrine Carcinoma Drugs Market Report 2017
- QYR2227642
- 98 Pages
- November 2017
- Pharmaceuticals
Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Neuroendocrine Carcinoma Drugs in these regions, from 2012 to 2022 (forecast).
United States Neuroendocrine Carcinoma Drugs market competition by top manufacturers/players, with Neuroendocrine Carcinoma Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Xiaflex
Novartis AG
Roche
Molecular Insight pharmaceuticals
Callisto Pharmaceuticals
...
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Somatostatin Analogs
Targeted Therapy
Chemotherapy
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Neuroendocrine Carcinoma Drugs Market Report 2017
1 Neuroendocrine Carcinoma Drugs Overview
1.1 Product Overview and Scope of Neuroendocrine Carcinoma Drugs
1.2 Classification of Neuroendocrine Carcinoma Drugs by Product Category
1.2.1 United States Neuroendocrine Carcinoma Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Neuroendocrine Carcinoma Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Somatostatin Analogs
1.2.4 Targeted Therapy
1.2.5 Chemotherapy
1.3 United States Neuroendocrine Carcinoma Drugs Market by Application/End Users
1.3.1 United States Neuroendocrine Carcinoma Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 United States Neuroendocrine Carcinoma Drugs Market by Region
1.4.1 United States Neuroendocrine Carcinoma Drugs Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Neuroendocrine Carcinoma Drugs Status and Prospect (2012-2022)
1.4.3 Southwest Neuroendocrine Carcinoma Drugs Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Neuroendocrine Carcinoma Drugs Status and Prospect (2012-2022)
1.4.5 New England Neuroendocrine Carcinoma Drugs Status and Prospect (2012-2022)
1.4.6 The South Neuroendocrine Carcinoma Drugs Status and Prospect (2012-2022)
1.4.7 The Midwest Neuroendocrine Carcinoma Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Neuroendocrine Carcinoma Drugs (2012-2022)
1.5.1 United States Neuroendocrine Carcinoma Drugs Sales and Growth Rate (2012-2022)
1.5.2 United States Neuroendocrine Carcinoma Drugs Revenue and Growth Rate (2012-2022)
2 United States Neuroendocrine Carcinoma Drugs Market Competition by Players/Suppliers
2.1 United States Neuroendocrine Carcinoma Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Neuroendocrine Carcinoma Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Neuroendocrine Carcinoma Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Neuroendocrine Carcinoma Drugs Market Competitive Situation and Trends
2.4.1 United States Neuroendocrine Carcinoma Drugs Market Concentration Rate
2.4.2 United States Neuroendocrine Carcinoma Drugs Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Neuroendocrine Carcinoma Drugs Manufacturing Base Distribution, Sales Area, Product Type
3 United States Neuroendocrine Carcinoma Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Neuroendocrine Carcinoma Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Neuroendocrine Carcinoma Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Neuroendocrine Carcinoma Drugs Price by Region (2012-2017)
4 United States Neuroendocrine Carcinoma Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Neuroendocrine Carcinoma Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Neuroendocrine Carcinoma Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Neuroendocrine Carcinoma Drugs Price by Type (2012-2017)
4.4 United States Neuroendocrine Carcinoma Drugs Sales Growth Rate by Type (2012-2017)
5 United States Neuroendocrine Carcinoma Drugs Sales (Volume) by Application (2012-2017)
5.1 United States Neuroendocrine Carcinoma Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Neuroendocrine Carcinoma Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Neuroendocrine Carcinoma Drugs Players/Suppliers Profiles and Sales Data
6.1 Xiaflex
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Neuroendocrine Carcinoma Drugs Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Novartis AG
6.2.2 Neuroendocrine Carcinoma Drugs Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Roche
6.3.2 Neuroendocrine Carcinoma Drugs Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Roche Neuroendocrine Carcinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Molecular Insight pharmaceuticals
6.4.2 Neuroendocrine Carcinoma Drugs Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Callisto Pharmaceuticals
6.5.2 Neuroendocrine Carcinoma Drugs Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
...
7 Neuroendocrine Carcinoma Drugs Manufacturing Cost Analysis
7.1 Neuroendocrine Carcinoma Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Neuroendocrine Carcinoma Drugs
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Neuroendocrine Carcinoma Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Neuroendocrine Carcinoma Drugs Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Neuroendocrine Carcinoma Drugs Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Neuroendocrine Carcinoma Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Neuroendocrine Carcinoma Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Neuroendocrine Carcinoma Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Neuroendocrine Carcinoma Drugs Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
Figure Product Picture of Neuroendocrine Carcinoma Drugs
Figure United States Neuroendocrine Carcinoma Drugs Market Size (K MT) by Type (2012-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Somatostatin Analogs Product Picture
Figure Targeted Therapy Product Picture
Figure Chemotherapy Product Picture
Figure United States Neuroendocrine Carcinoma Drugs Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Neuroendocrine Carcinoma Drugs by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinics Examples
Table Key Downstream Customer in Clinics
Figure Oncology Centres Examples
Table Key Downstream Customer in Oncology Centres
Figure Ambulatory Surgery Centres Examples
Table Key Downstream Customer in Ambulatory Surgery Centres
Figure United States Neuroendocrine Carcinoma Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales (K MT) and Growth Rate (2012-2022)
Figure United States Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Neuroendocrine Carcinoma Drugs Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Neuroendocrine Carcinoma Drugs Sales Share by Players/Suppliers
Figure 2017 United States Neuroendocrine Carcinoma Drugs Sales Share by Players/Suppliers
Figure United States Neuroendocrine Carcinoma Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Neuroendocrine Carcinoma Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Neuroendocrine Carcinoma Drugs Revenue Share by Players/Suppliers
Table United States Market Neuroendocrine Carcinoma Drugs Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Neuroendocrine Carcinoma Drugs Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Neuroendocrine Carcinoma Drugs Market Share of Top 3 Players/Suppliers
Figure United States Neuroendocrine Carcinoma Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Neuroendocrine Carcinoma Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Neuroendocrine Carcinoma Drugs Product Category
Table United States Neuroendocrine Carcinoma Drugs Sales (K MT) by Region (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales Share by Region (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Share by Region (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Market Share by Region in 2016
Table United States Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Revenue Share by Region (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Revenue Market Share by Region (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Revenue Market Share by Region in 2016
Table United States Neuroendocrine Carcinoma Drugs Price (USD/MT) by Region (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales (K MT) by Type (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales Share by Type (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Share by Type (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Market Share by Type in 2016
Table United States Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Neuroendocrine Carcinoma Drugs by Type (2012-2017)
Figure Revenue Market Share of Neuroendocrine Carcinoma Drugs by Type in 2016
Table United States Neuroendocrine Carcinoma Drugs Price (USD/MT) by Types (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Growth Rate by Type (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales (K MT) by Application (2012-2017)
Table United States Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Market Share by Application in 2016
Table United States Neuroendocrine Carcinoma Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Neuroendocrine Carcinoma Drugs Sales Growth Rate by Application (2012-2017)
Table Xiaflex Basic Information List
Table Xiaflex Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Xiaflex Neuroendocrine Carcinoma Drugs Sales Growth Rate (2012-2017)
Figure Xiaflex Neuroendocrine Carcinoma Drugs Sales Market Share in United States (2012-2017)
Figure Xiaflex Neuroendocrine Carcinoma Drugs Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Novartis AG Neuroendocrine Carcinoma Drugs Sales Growth Rate (2012-2017)
Figure Novartis AG Neuroendocrine Carcinoma Drugs Sales Market Share in United States (2012-2017)
Figure Novartis AG Neuroendocrine Carcinoma Drugs Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Roche Neuroendocrine Carcinoma Drugs Sales Growth Rate (2012-2017)
Figure Roche Neuroendocrine Carcinoma Drugs Sales Market Share in United States (2012-2017)
Figure Roche Neuroendocrine Carcinoma Drugs Revenue Market Share in United States (2012-2017)
Table Molecular Insight pharmaceuticals Basic Information List
Table Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales Growth Rate (2012-2017)
Figure Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales Market Share in United States (2012-2017)
Figure Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Revenue Market Share in United States (2012-2017)
Table Callisto Pharmaceuticals Basic Information List
Table Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales Growth Rate (2012-2017)
Figure Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales Market Share in United States (2012-2017)
Figure Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neuroendocrine Carcinoma Drugs
Figure Manufacturing Process Analysis of Neuroendocrine Carcinoma Drugs
Figure Neuroendocrine Carcinoma Drugs Industrial Chain Analysis
Table Raw Materials Sources of Neuroendocrine Carcinoma Drugs Major Players/Suppliers in 2016
Table Major Buyers of Neuroendocrine Carcinoma Drugs
Table Distributors/Traders List
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Price (USD/MT) Trend Forecast (2017-2022)
Table United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Type in 2022
Table United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Application in 2022
Table United States Neuroendocrine Carcinoma Drugs Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Neuroendocrine Carcinoma Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Neuroendocrine Carcinoma Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
